Hepatitis C virus infection in the human immunodeficiency virus infected patient

Table 1 Interferon-free clinical trials conducted in human immunodeficiency virus - hepatitis C virus coinfected individuals

Direct acting antiviral			Ribavirin	Study name/identifier1	Patient population	Phase	Primary endpoint	Presented results
Ns3/4a protease inhibitor	Ns5b polymerase inhibitors	Ns5a inhibitors
No	Sofosbuvir	No	Yes	Photon-I (Ncto1667731)	GT 1:	3	SVR 12	GT 1: 76%2
					TN and IFN ineligible			GT 2: 88%
					GT 2 + 3: TE			GT 3: 67%
No	Sofosbuvir	No	Yes	Ncto1783678	GT 1 + 2 + 3 + 4:	3	SVR 12	No
					TN and IFN ineligible
					GT 2 + 3: TE
ABT-450(r)	ABT-333	ABT-267	Yes	Turquoise I (Ncto1939197)	GT 1	3	SVR 12	No
					TN + TE
MK-5172	No	MK-8742	Yes	c-WORHTy (Ncto01717326)	GT 1	2	SVR 12	No

¹ClinicalTrials.gov;

²Preliminary data presented at the Conference on Retroviruses And Opportunistic Infections, 2014. GT: Hepatitis C virus genotype; TN: Treatment naive; IFN: Interferon; TE: Treatment experienced; SVR: Sustained virological response; r: Ritonavir boosted.

Table 2 Treatment strategies including direct-acting antivirals in combination with ribavirin with or without pegylated interferon conducted in hepatitis C virus infected individuals with human immunodeficiency virus infection

Direct acting antiviral			Ribavirin/Peg Inf	Study name/ identifier1	Treatment duration	Phase	Primary endpoint	Presented results
Ns3/4a protease inhibitor	Ns5b polymerase inhibitors	Ns5a inhibitors
Boceprevir	No	No	Yes	NCT00959699	48 wk	APPROVED	SVR24	GT 1: 63%[123]
								Telaprevir	No	No	Yes	NCT00983853	48 wk	APPROVED	SVR12	GT 1: 74%[124]
Simeprevir	No	No	Yes	C212	24/48 wk2	III3	SVR12	GT 1: 79%-87%
				NCT01479868
Faldaprevir	No	No	Yes	Startverso4	24/48 wk2	III	SVR12	GT 1: 71%-72%
				NCT01399619

¹ClinicalTrials.gov;

²Simeprevir/faldaprevir+pegIFN/RBV for 12-24 wk, then pegIFN/RBV for 12-24 wk;

³Approved in HCV monoinfected with HCV genotype 1. RBV: Ribavirin; GT: Hepatitis C virus genotype; TN: Treatment naive; IFN: Interferon; TE: Treatment experienced; SVR: Sustained virological response; r: Ritonavir boosted.

Table 3 Current and future treatment strategies for chronic hepatitis C virus infected patients

Treatment strategy	Compounds	Genotype 1	Genotype 2	Genotype 3	Genotype 4	Genotype 5	Genotype 6
Interferon Based	Sofosbuvir	×	×	×	×	×	×
	Simeprevir	×			×
	Daclatasavir	×		×	×	×	×
Interferon free	Sofosbuvir + ribavirin		×	×
	Sofosbuvir + simeprevir	×			×
	Sofosbuvir + daclatasavir	×		×	×	×	×